← All companies ← QFIN Manual QH → ← QDEL Biotechnology RGEN →
QGEN, Qiagen N.V.
A pharmaceutical business, where patents grant a temporary monopoly the pipeline must keep refilling.
The business
What it sells, where the money comes from, the kind of company it is.
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Cyclical. Margins collapse and recover repeatedly across the record; a single year, good or bad, misstates the through-cycle earning power.
- What moves the needle
- Gross margin has run about 64% and operating margin about 18% through the cycle, a wide spread between price and the cost of what it sells — whether that advantage is durable pricing power or a margin that can erode is the question the record is for. The margin is cyclical, swinging between −1.7% and 28% over the years, so the through-cycle figure carries more than any single year — and the balance sheet at the trough more than the peak. Inventory runs near 14% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on customer concentration, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has rarely cleared the cost of capital (median 7%, above 15% in 0 of 10 years). By owner earnings: roughly 19% of revenue reaches owners as cash, consistently. The cycle and the balance sheet decide this one; the worst year tells more than the median, and the rest is in the 10-K.
Every line is arithmetic on the company's filings, shown in full in the sections below.
Where the money comes from
read the 20-F →Revenue spreads across 5 regions, the largest United States at 48%.
- United States48%$998M
- EMEA34%$713M
- Asia Pacific and Rest of World14%$291M
- Other Americas4%$88M
- Netherlands1%$24M
From the segment footnote of the company's own 20-F. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.
The record
Ten years of arithmetic, read across the cycle.
The record, 2016–2025
realized figures from each filing · older years to the left| 2016’16 | 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMDec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| $1.3B | $1.4B | $1.5B | $1.5B | $1.9B | $2.3B | $2.1B | $2.0B | $2.0B | $2.1B | $2.1B | RevenueRevenue |
| 63% | 65% | 67% | 66% | 66% | 64% | 65% | 63% | 49% | 62% | 62% | Gross marginGross mgn |
| $99M | $153M | $267M | ($26M) | $386M | $630M | $531M | $410M | $98M | $466M | $466M | Operating incomeOp. inc. |
| 7.4% | 10.8% | 17.8% | −1.7% | 20.7% | 28.0% | 24.8% | 20.9% | 4.9% | 22.3% | 22.3% | Operating marginOp. mgn |
| $80M | $40M | $190M | ($41M) | $359M | $513M | $423M | $341M | $84M | $425M | ($41M) | Net incomeNet inc. |
| — | — | 16% | — | 18% | 18% | 17% | 21% | 31% | 13% | — | Effective tax rateTax rate |
| Cash flow & returns | |||||||||||
| $342M | $287M | $359M | $331M | $458M | $639M | $715M | $459M | $674M | $654M | $654M | Operating cash flowOp. cash |
| $213M | $216M | $206M | $231M | $205M | $215M | $208M | $205M | $203M | $194M | $194M | DepreciationDeprec. |
| $48M | $30M | ($37M) | $141M | ($106M) | ($89M) | $84M | ($87M) | $387M | $36M | $502M | Working capital & otherWC & other |
| $75M | $90M | $110M | $118M | $133M | $190M | $129M | $150M | $167M | $201M | $201M | CapexCapex |
| 5.6% | 6.4% | 7.3% | 7.7% | 7.1% | 8.4% | 6.0% | 7.6% | 8.5% | 9.6% | 9.6% | Capex / revenueCapex/rev |
| $267M | $197M | $250M | $213M | $325M | $449M | $586M | $310M | $506M | $453M | $453M | Owner earningsOwner earn. |
| 20.0% | 13.9% | 16.6% | 13.9% | 17.4% | 19.9% | 27.4% | 15.8% | 25.6% | 21.7% | 21.7% | Owner earnings marginOE mgn |
| $267M | $197M | $250M | $213M | $325M | $449M | $586M | $310M | $506M | $453M | $453M | Free cash flowFCF |
| 20.0% | 13.9% | 16.6% | 13.9% | 17.4% | 19.9% | 27.4% | 15.8% | 25.6% | 21.7% | 21.7% | Free cash flow marginFCF mgn |
| — | — | — | — | — | — | — | $0 | $0 | $54M | $54M | Dividends paidDiv. paid |
| $0 | $61M | $105M | $74M | $64M | $100M | $0 | $0 | $292M | $280M | — | BuybacksBuybacks |
| 3% | 2% | 6% | -1% | 8% | 12% | 10% | 7% | 2% | 9% | — | ROICROIC |
| 3% | 2% | 7% | -2% | 13% | 17% | 12% | 9% | 2% | 11% | -1% | Return on equityROE |
| — | — | — | — | — | — | — | 9% | 2% | 10% | −3% | Retained to equityRetained/eq |
| Balance sheet | |||||||||||
| $532M | $1.0B | $1.4B | $753M | $715M | $1.1B | $1.4B | $1.1B | $1.2B | $1.1B | $1.1B | Cash & investmentsCash+inv |
| $278M | $329M | $352M | $385M | $381M | $362M | $324M | $382M | $349M | $403M | $403M | ReceivablesReceiv. |
| $137M | $156M | $163M | $171M | $291M | $328M | $358M | $398M | $279M | $302M | $302M | InventoryInvent. |
| $51M | $59M | $69M | $85M | $118M | $101M | $99M | $84M | $83M | $73M | $73M | Accounts payablePayables |
| $364M | $426M | $445M | $471M | $554M | $588M | $583M | $696M | $545M | $632M | $632M | Operating working capitalOper. WC |
| $1.0B | $1.6B | $2.2B | $1.6B | $1.6B | $2.1B | $2.4B | $2.1B | $2.0B | $2.0B | $2.0B | Current assetsCur. assets |
| $308M | $325M | $972M | $951M | $572M | $1.5B | $975M | $1.1B | $1.0B | $512M | $512M | Current liabilitiesCur. liab. |
| 3.4× | 5.1× | 2.2× | 1.7× | 2.8× | 1.4× | 2.5× | 2.0× | 1.9× | 3.9× | 3.9× | Current ratioCurr. ratio |
| $1.9B | $2.0B | $2.1B | $2.1B | $2.4B | $2.4B | $2.4B | $2.5B | $2.4B | $2.7B | $2.7B | GoodwillGoodwill |
| $4.3B | $5.0B | $5.7B | $5.2B | $5.9B | $6.1B | $6.3B | $6.1B | $5.7B | $6.3B | $6.3B | Total assetsAssets |
| $1.1B | $1.8B | $2.2B | $1.7B | $1.9B | $1.9B | $1.9B | $1.5B | $1.4B | $1.7B | $1.7B | Total debtDebt |
| $535M | $741M | $781M | $953M | $1.2B | $876M | $443M | $452M | $239M | $556M | $556M | Net debt / (cash)Net debt |
| 2.5× | 3.1× | 4.0× | -0.4× | 5.4× | 11.6× | 9.1× | 7.7× | 2.2× | 14.0× | 8.7× | Interest coverageInt. cov. |
| $2.6B | $2.5B | $2.6B | $2.5B | $2.8B | $3.1B | $3.5B | $3.8B | $3.6B | $3.8B | $3.8B | Shareholders’ equityEquity |
| Per share | |||||||||||
| 239M | 233M | 233M | 227M | 234M | 232M | 230M | 231M | 225M | 219M | 236M | Shares out (diluted)Shares |
| $5.60 | $6.08 | $6.43 | $6.73 | $7.99 | $9.70 | $9.31 | $8.52 | $8.80 | $9.55 | $8.84 | Revenue / shareRev/sh |
| $0.34 | $0.17 | $0.82 | $-0.18 | $1.53 | $2.21 | $1.84 | $1.48 | $0.37 | $1.94 | $-0.18 | EPS (diluted)EPS |
| $1.12 | $0.84 | $1.07 | $0.94 | $1.39 | $1.94 | $2.55 | $1.34 | $2.25 | $2.07 | $1.92 | Owner earnings / shareOE/sh |
| $1.12 | $0.84 | $1.07 | $0.94 | $1.39 | $1.94 | $2.55 | $1.34 | $2.25 | $2.07 | $1.92 | Free cash flow / shareFCF/sh |
| — | — | — | — | — | — | — | $0.00 | $0.00 | $0.25 | $0.23 | Dividends / shareDiv/sh |
| $0.31 | $0.39 | $0.47 | $0.52 | $0.57 | $0.82 | $0.56 | $0.65 | $0.74 | $0.92 | $0.85 | Cap. spending / shareCapex/sh |
| $10.91 | $10.91 | $11.29 | $11.19 | $11.95 | $13.35 | $15.06 | $16.51 | $15.87 | $17.26 | $15.98 | Book value / shareBVPS |
| 9-yr | 5-yr | |
|---|---|---|
| Revenue / share | +6.1%/yr | +3.6%/yr |
| Owner earnings / share | +7.1%/yr | +8.3%/yr |
| EPS | +21.5%/yr | +4.8%/yr |
| Capital spending / share | +12.8%/yr | +10.1%/yr |
| Book value / share | +5.2%/yr | +7.6%/yr |
The record, charted
FY2016–2025Each measure over its full record; the current point and the worst year marked.
Owner earnings vs. net income
Owner earningsNet incomeThe accountant's number, and the cash an owner can take; the gap is the tell.
Where the cash went
ReinvestBuybacksDividendsAcquisitionsRetainedEach year's operating cash, by what management did with it: the mix, and how it drifts.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business turned $425M of profit into $453M of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Reported net income | $425M | $84M | $341M | $423M | $513M |
| Depreciation & amortizationnon-cash charge added back | +$194M | +$203M | +$205M | +$208M | +$215M |
| Working capital & othertiming of cash in and out, other non-cash items | +$36M | +$387M | −$87M | +$84M | −$89M |
| Cash from operations | $654M | $674M | $459M | $715M | $639M |
| Capital expenditurecash put back in to keep running and to grow | −$201M | −$167M | −$150M | −$129M | −$190M |
| Owner earnings | $453M | $506M | $310M | $586M | $449M |
| Owner-earnings marginowner earnings ÷ revenue | 22% | 26% | 16% | 27% | 20% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
Will it survive?
- ComfortableOperating income $466M ÷ interest expense $53M
What this means
Operating profit covers interest with the kind of margin Graham wanted for a defensive holding. Necessary, not sufficient, it says solvent, not cheap.
- How heavy is the debt, net of cash? $556M · 1.2× operating profitModest net debtCash $839M + ST investments $260M − debt $1.7B
What this means
Netting $1.1B of cash and short-term investments against $1.7B of debt leaves $556M owed, about 1.2× a year's operating profit (3.6× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Long (60+ days)DSO 70 + DIO 139 − DPO 34 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- Below average through the cycle10-yr median, range -1%–12%; the latest year is left out — large non-operating charges put its operating line well above pretax profitIndustry peers: median 9%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years, so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- High through the cycle10-yr median margin, range 14%–27%; latest $453M = operating cash $654M − maintenance capex $201MIndustry peers: median 21%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 22% of revenue this year, a 17% median across 10 years.
- Loss, but cash-generativeNet income ($41M) · cash from operations $654M
What this means
The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did.
How is the cash used?
- Returns about halfDividends + buybacks $334M ÷ Owner Earnings $453M
What this means
Of $453M Owner Earnings, $334M (74%) went back to shareholders, $54M dividends, $280M buybacks. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.
- Investing or harvesting? 1.04×MaintainingCapex $201M ÷ depreciation $194M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 3 of 6 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size PassRevenue ≥ $2B · $2.1B
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity PassCurrent ratio ≥ 2× · 3.90×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt NearDebt ≤ working capital · $1.7B vs $1.5B WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability NearA profit every year (10-yr record) · 1 loss year
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record MissUninterrupted dividends · 1 of 10 yrs
What this means
An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.
- Earnings growth PassEarnings +33% over the record · +173%
What this means
At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $1.31/share (latest year $-0.19), the averaged base the calculator's gate runs on, and book value is $17.42/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2016–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 9 of 10
What this means
Lost money in 1 year(s), look at what happened there before trusting the average.
- Return on capital ≥ 15% 0 of 10 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin 12% → 16% (3-yr avg ends)
What this means
Through the cycle the operating margin widened — about 12% early to 16% lately, median 18% — pricing power intact or improving.
- Reinvestment, incremental ROIC returns capital
What this means
The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.
- Owner earnings growth +8%/yr
What this means
Owner earnings grew about 8% a year over the record.
- Worst year 2019 · −1.7% op. margin
What this means
Operations went underwater in 2019, understand why before trusting the good years.
- Share count −1.0%/yr
What this means
The share count is shrinking, buybacks are quietly growing your slice of the business.
- Dividend record paid
What this means
Paid a dividend in 1 of the years on record.
Does AI threaten the moat?
Low contestabilityThe moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.
Its FY2025 10-K names artificial intelligence as a competitive threat, in language that was not in the prior year's filing.
“Advancements in artificial intelligence—including AI driven bioinformatics, automated interpretation tools and competitive AI curated data platforms—may accelerate innovation cycles and shift customer expectations.”
AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.
Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.
All figures as filed; the source filing is linked above.
Current Position
as of fiscal year-end, Dec 31, 2025Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$1.1B
- Receivables$403M
- Inventory$302M
- Other current assets$192M
- Accounts payable$73M
- Other current liabilities$439M
From the company's latest filing.
How the cash was used, 2016–2025
Over the record, the business generated $4.9B of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.
- Reinvested$1.4B · 28%
- Dividends$54M · 1%
- Buybacks$976M · 20%
- Retained (debt / cash)$2.5B · 51%
- Returned to owners$1.0B
29% of the owner earnings the business produced over the span, $54M as dividends and $976M as buybacks.
- Average price paid for buybacks—
Buybacks ran $976M over the span, but the filings don't tag the share count needed to deduce the average price paid.
- Net change in share count−1.0%
The diluted count fell from 239M to 236M, so the buybacks outran the stock issued to staff.
- Dividend record$0.25/sh
Paid in 1 of the years on record. It was never cut over the span.
- Return on what it retained13%
Of the earnings it kept rather than paid out ($1.4B over the span), annual owner earnings (first three years vs last three) grew $185M, so each retained $1 added about 0.13 of yearly owner earnings. Buffett's test, run on owner earnings instead of market value.
Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.
Acquisitions & goodwill
from the balance sheet & the 10-year cash-flow recordGoodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.
None written down over the record; the goodwill is still carried at full cost. That is the deals holding their value on the books so far; whether they keep doing so is the test an owner watches, since the write-down, when it comes, is the admission the price was too high.
Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend and write-downs summed across the 10-year record, from the company's own filings.
Inverting the record
Invert: instead of why Qiagen N.V. is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2016–2025.
None of the 5 tests turned up a mark; each came back clean. A clean panel says only that these particular ways of being wrong are not written into the record.
- Is it less profitable than it was?
- Did the share count rise anyway?
- Did debt outgrow the business?
- Did reported profit become cash?
- Did receivables and inventory outpace sales?
Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.
Peers, Biotechnology
The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| NBIXNeurocrine | $2.9B | 99% | 11.2% | 10% | 21% |
| EXELExelixis Inc. | $2.3B | 96% | 23.9% | 18% | 34% |
| QGENQiagen N.V. | $2.1B | 65% | 19.2% | 7% | 19% |
| MRNAModerna Inc. | $1.9B | 55% | -126.4% | -35% | -77% |
| SRPTSarepta | $1.9B | — | -93.0% | -25% | -63% |
| HALOHalozyme | $1.4B | 83% | 37.1% | 17% | 39% |
| TECHBio-Techne | $1.2B | 67% | 21.4% | 9% | 22% |
| NVAXNovavax Inc. | $1.1B | 65% | -117.4% | -128% | -50% |
| Group median | — | 67% | 15.2% | 8% | 20% |
The price
What a price has to assume.
What the price implies
reverse-DCFEnter the US price, in dollars: the NYSE/Nasdaq quote you hold. Qiagen N.V.'s US listing is the ordinary share itself. The record tables elsewhere on this page remain as filed.
Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Qiagen N.V. has delivered.
Qiagen N.V.’s latest year runs above its own through-cycle margin — the reported figure may flatter a peak. So the tool opens on the through-cycle base, Graham’s averaging cutting both ways; clear the toggle below to read the latest year exactly as reported.
Through the cycle, Qiagen N.V. earns about $390M on its 18.7% median owner-earnings margin. This year’s 21.7% margin runs above that; the reported figure may flatter a peak you'd be paying on. Normalize, below, values the price on that through-cycle figure rather than the latest year. It comes pre-checked here for that reason, the same rule that already normalizes a trough; clear it to price the year as filed.
—
9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Owner earnings $453M on 217M shares outstanding, per the 20-F cover, as of 2025-12-31; net debt $556M. The if-converted diluted count is 236M, 9% above the shares outstanding: the dilution overhang (convertibles, options) a buyer inherits. The base opens on the through-cycle figure (the latest year sits above the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Manual order: ← QFIN its page in the Manual QH →
Industry order: ← QDEL the Biotechnology chapter RGEN →